OraSure Technologies, Inc.

NASDAQ:OSUR

Medical - Instruments & Supplies

Healthcare
$3.59 -3.47%

-$0.16 today

Market cap
$247.88M
Beta
1.01
P/E (TTM)
-4.0
EPS (TTM)
-$1.08
52W Low $2.08High $4.58

Volume 0.49M

Average 0.61M

OSUR Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

OraSure Technologies, Inc.NASDAQ: OSUR

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures growth accelerates

Q1 FY2026 capital expenditures of $913K (cash outflow) rose 117.4% year over year, ahead of the +77.8% change in trailing-twelve-month capital expenditures. Sequentially, it fell 1.0% from the prior quarter. Over 3 fiscal years it compounded at -96.0% a year.

Context

  • Capital expenditures amounted to 0.0% of revenue in FY2025, down 2.0 pp from a year earlier.
  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +117.4% holds above the trailing-twelve-month pace of +77.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$913K-1.0% QoQ
Last fiscal yearDec 2025
-$4.2K-99.9% YoY
LTMMar 2026
-$4.69M+77.8% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+117.4%——
1 year-99.9%——
3-year CAGR-96.0%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(4.2K) USD
Year-over-year change
+99.9%

Capital Expenditures vs competitors

How OSUR compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +77.8% is the 2nd highest of 7, against a peer median of -46.9%.
  • Capital expenditures amounts to 4.1% of revenue for OSUR, versus a peer median of 0.9%.
OSUR Competitors
Capital Expenditures for OSUR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$14.95M USD-70.1%+248.2%2419.3%
OSUROraSure Technologies, Inc.LTM Mar 2026$4.69M USD+77.8%-96.0%4.1%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$1.57M USD-7.4%-18.1%—
NYXHNyxoah S.A.LTM Mar 2026€1.32M EUR-65.8%-63.4%8.1%
STIMNeuronetics, Inc.LTM Mar 2026$779K USD-40.5%-37.4%0.5%
UTMDUtah Medical Products, Inc.LTM Mar 2026$317K USD+85.4%-23.2%0.8%
PREPrenetics Global LimitedLTM Mar 2026$208K USD—-68.0%0.2%
PROFProfound Medical Corp.LTM Mar 2026$179.08K USD——0.9%
TARAProtara Therapeutics, Inc.LTM Mar 2026$50K USD-53.3%-7.8%—
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$8 USD———
Peer median (excluding OSUR) —-46.9%-23.2%0.9%

Competitors are the stored peer set for OSUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23M)(17.93M)53.66M(19.5M)(68.73K)
Depreciation & Amortization12.5M15.54M20.94M10.87M10.19K
Deferred Income Tax1.03M(1.65M)102K(657K)(103)
Stock-Based Compensation7.81M11.62M10.73M11.92M10.15K
Change in Working Capital(38.44M)(70.56M)45.76M18.82M(6.8M)
Accounts Receivables(6.45M)(25.16M)31.12M15.87M1.95M
Inventory(27.94M)(43.05M)48.23M13.1M3.56M
Accounts Payables3.23M3.96M(26.98M)(7.58M)(1.72M)
Other Working Capital(7.28M)(6.32M)(6.61M)(2.57M)(10.59M)
Other Non-Cash Items4.72M15.79M10.4M5.92M6.8M
Operating Cash Flow(35.38M)(47.2M)141.58M27.37M(49.02K)
Capital Expenditures(48.12M)(63.91M)(10.3M)(3.8M)(4.2K)
Acquisitions (Net)0121K0(5.04M)(3.61K)
Purchases of Investments(25.82M)(22.87M)(74.65M)(53.24M)0
Sales of Investments67.93M47.42M102.44M53.05M0
Other Investing Activities513K60.33M48.67M(30M)1K
Investing Cash Flow(5.5M)21.09M66.15M(39.03M)(6.81K)
Debt Repayment(686K)(1.38M)(1.35M)(842K)(61K)
Common Stock Issued00000
Common Stock Repurchased(2.11M)(2.25M)(1.9M)(3.55M)(15.04M)
Dividends Paid00000
Other Financing Activities(18K)(193K)223K214K15.08M
Financing Cash Flow(2.82M)(3.83M)(3.02M)(4.18M)(16.94K)
Effect of Forex Changes(340K)(2.84M)1.71M(6.82M)4.29K
Net Change in Cash(44.04M)(32.78M)206.43M(22.64M)(68.49K)
Free Cash Flow(83.5M)(111.11M)131.28M23.58M(53.22K)

OraSure Technologies, Inc.

NASDAQ:OSUR

Intrinsic Alpha fair value

Locked

Current Price

$3.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.